Contraception
Volume 78, Issue 6 , Pages 451-458 , December 2008

Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis

  • Jeffrey T. Jensen

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA
    • Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    • Corresponding Author InformationCorresponding author. Mail code UHN-70 Oregon Health and Science University, Portland, OR 97239, USA. Tel.: +1 503 494 4469; fax: +1 503 494 5083.
    • ,
  • Anne E. Burke

      Affiliations

    • Department of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, MD 21205, USA
    • ,
  • Kurt T. Barnhart

      Affiliations

    • Department of Obstetrics and Gynecology, and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Carrie Tillotson

      Affiliations

    • Biostatistics Shared Resource, Oregon Health and Science University, Portland, OR 97239, USA
    • ,
  • Marci Messerle-Forbes

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA
    • ,
  • Dawn Peters

      Affiliations

    • Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR 97239, USA

Received 8 May 2008 ,Revised 2 July 2008 ,Accepted 3 July 2008.

References 

  1. van den Heuvel MW, van Bragt AJ, Alnabawy AK, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168–174
  2. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527–1535
  3. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, et al. Estrogens, progestogens and thrombosis. J Thromb Haemost. 2003;1:1371–1380
  4. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 2001;358:1427–1429
  5. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:131–134
  6. Srivastava A, Weiss M. First Patch Death; Coroner confirms it. New York Post. April 28, 2004, 2004: 13.
  7. Edelman S, Kranes M. ‘Patch’ shock grows: kin ID new ‘victims’. New York Post. May 16, 2004, 2004: 1.
  8. Cole JA, Norman H, Doherty M, et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109:339–346
  9. Jick S, Kaye JA, Li L, et al. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2007;76:4–7
  10. Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2006;73:223–228
  11. Teal S.B., Ginosar D.M. Contraception for women with chronic medical conditions. Obstet Gynecol Clin North Am 2007;34:113–126, ix.
  12. Cornelis K, Piet M, Katherine DL, et al. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception. 2008;77:77–83
  13. Johnson JV, Lowell J, Badger GJ, et al. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol. 2008;111:278–284
  14. White T, Ozel B, Jain JK, et al. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception. 2006;74:293–296
  15. Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol. 2008;111:267–277
  16. Thomas AE, McKay DA, Cutlip MB. A nomograph method for assessing body weight. Am J Clin Nutr. 1976;29:302–304
  17. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47:277–283
  18. Rosing J, Tans G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol. 1999;180:S375–S382
  19. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol. 2003;122:465–470
  20. Rosen SB, Sturk A. Activated protein C resistance — a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem. 1997;35:501–516
  21. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol. 1999;105:88–94
  22. Odlind V, Milsom I, Persson I, et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand. 2002;81:482–490
  23. van Rooijen M, Silveira A, Hamsten A, et al. Sex hormone-binding globulin — a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol. 2004;190:332–337
  24. Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf). 1974;3:69–96
  25. El Makhzangy MN, Wynn V, Lawrence DM. Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin Endocrinol (Oxf). 1979;10:39–45
  26. Knopp RH, Broyles FE, Cheung M, et al. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception. 2001;63:1–11
  27. van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 1990;41:345–352
  28. van Kammen E, Thijssen JH, Rademaker B, et al. The influence of hormonal contraceptives on sex hormone binding globulin (SHBG) capacity. Contraception. 1975;11:53–59
  29. Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol. 2003;1:111
  30. Clarkson TB, Shively CA, Morgan TM, et al. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol. 1990;75:217–222
  31. Blickstein I. Thrombophilia and women's health: an overview. Obstet Gynecol Clin North Am. 2006;33:347–356

☆ This publication was made possible in part with biostatistics support from the Biostatistics Shared Resource of Oregon Health and Science University and laboratory support from the Oregon Clinical and Translational Research Institute (OCTRI), grant numbers UL1 RR024140 01 and M01 RR000334 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Funding for the main study was directly from the Magee-Women's Research Institute Foundation using funds from Organon USA. Organon USA, Inc., played no role in the design of either study; in the acquisition, analysis and interpretation of the data; in the drafting or revision of the manuscript; or technical support or supervision of the study.

☆☆ Conflict of interest: Dr. Jensen: research funding: Bayer, Organon, Galen, Symbollon, Wyeth, Pfizer, Novartes; speakers bureau: Bayer, Wyeth; consulting: Bayer, Wyeth, Novartes. Dr. Burke: research funding: Organon, Duramed, Bayer. Dr. Barnhart: research funding: Organon, Wyeth-Ayerst, Johnson & Johnson, Duramed, Xanodyne, Boehringer Ingelheim, Third Wave, Pfeizer, MGI Pharma; speakers bureau: Organon; consulting: Novo Nordisk. Dr. Peters, Ms. Messerle-Forbes and Ms. Tillotson: no conflicts.

PII: S0010-7824(08)00368-5

doi: 10.1016/j.contraception.2008.07.004

Contraception
Volume 78, Issue 6 , Pages 451-458 , December 2008

Article Tools

* Image Usage & Resolution